Arcellx, Inc.
ACLX
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic coā¦ read more
Healthcare
Biotechnology
2 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$72.24
Price+0.11%
$0.08
1Y
Price
Market Cap
$4.006b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-38.2%
EBITDA Margin-18.3%
Net Profit Margin-97.7%
Free Cash Flow MarginRevenue
$56.979m
+19.4%
1y CAGR+6.5%
3y CAGR+4.8%
5y CAGREarnings
-$187.989m
+28.5%
1y CAGR-33.5%
3y CAGR-49.9%
5y CAGREPS
-$3.43
+27.2%
1y CAGR-14.5%
3y CAGR-32.5%
5y CAGRBook Value
$392.223m
$619.086m
Assets$226.863m
Liabilities$52.513m
DebtDebt to Assets
8.5%
-1.3x
Debt to EBITDAFree Cash Flow
-$123.243m
-117.9%
1y CAGR+32.1%
3y CAGR-1.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company